AUTHOR=Li Xiaoli , Zhou Ping , Li Qiu , Peng Bin , Cun Yupeng , Dai Ying , Wei Hua , Liu Xiao , Yu Yang , Jiang Zhiyang , Fan Qiongli , Zhang Yuping , Yang Ting , Chen Jie , Cheng Qian , Li Tingyu , Chen Li 

TITLE=Regressive Autism Spectrum Disorder: High Levels of Total Secreted Amyloid Precursor Protein and Secreted Amyloid Precursor Protein-α in Plasma

JOURNAL=Frontiers in Psychiatry

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.809543

DOI=10.3389/fpsyt.2022.809543

ISSN=1664-0640

ABSTRACT=<p>Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by social communication difficulties, repetitive behaviors, and parochial interests. Individuals with regressive ASD (RA), a unique subtype, have poor outcomes. Moreover, there are currently no validated blood-based biomarkers for ASD, hindering early diagnosis and treatment. This study was the first to examine plasma levels of total secreted amyloid precursor protein (sAPPtotal), secreted amyloid precursor protein-α (sAPPα), and secreted amyloid precursor protein-β (sAPPβ) in children diagnosed with RA (<italic>n</italic> = 23) and compare them with the levels in age-matched children with non-regressive ASD (NRA) (<italic>n</italic> = 23) and typically developing (TD) controls (<italic>n</italic> = 23). We found that sAPPtotal and sAPPα levels were significantly higher in children with RA than in children with NRA or in TD controls. In contrast, no difference was observed in sAPPβ levels. In conclusion, increased plasma levels of sAPPtotal and sAPPα may be valuable biomarkers for the early identification of ASD regression. Prospective studies will be conducted using a larger sample to further investigate these differences.</p>